Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have been given a consensus rating of "Buy" by the nine brokerages that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $336.30.
Several analysts have weighed in on the company. Zacks Research raised BeOne Medicines from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 18th. Barclays assumed coverage on BeOne Medicines in a report on Thursday, September 18th. They issued an "overweight" rating and a $385.00 price target on the stock. JPMorgan Chase & Co. raised their price target on BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. Royal Bank Of Canada raised their price target on BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Finally, Wall Street Zen cut BeOne Medicines from a "strong-buy" rating to a "buy" rating in a report on Friday, September 5th.
Check Out Our Latest Analysis on ONC
BeOne Medicines Price Performance
NASDAQ ONC traded down $7.79 during trading hours on Friday, hitting $330.03. The company had a trading volume of 85,157 shares, compared to its average volume of 420,661. BeOne Medicines has a 52 week low of $170.99 and a 52 week high of $351.27. The firm has a 50 day simple moving average of $310.42 and a 200 day simple moving average of $268.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95. The firm has a market capitalization of $36.19 billion, a price-to-earnings ratio of -190.77 and a beta of 0.21.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. Equities research analysts expect that BeOne Medicines will post -5.82 earnings per share for the current year.
Insider Activity at BeOne Medicines
In related news, insider Lai Wang sold 5,000 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total transaction of $1,750,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John Oyler sold 27,803 shares of the firm's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $325.71, for a total value of $9,055,715.13. The disclosure for this sale can be found here. Insiders sold a total of 181,315 shares of company stock worth $54,839,498 in the last quarter. 6.62% of the stock is owned by company insiders.
Hedge Funds Weigh In On BeOne Medicines
Large investors have recently bought and sold shares of the stock. Anchor Investment Management LLC purchased a new position in BeOne Medicines in the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $28,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $35,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $39,000. Finally, Signaturefd LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter worth approximately $49,000. 48.55% of the stock is owned by hedge funds and other institutional investors.
BeOne Medicines Company Profile
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.
Further Reading
Before you consider BeOne Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BeOne Medicines wasn't on the list.
While BeOne Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
